Cellzome Announces Achievement of First Milestone in Inflammation Alliance with GlaxoSmithKline
News Dec 11, 2008
Cellzome Inc. announced that it has successfully achieved the first milestone in the strategic alliance with GlaxoSmithKline (GSK) established earlier this year, triggering payment of an undisclosed amount.
In September this year, Cellzome and GSK announced the signing of a worldwide strategic alliance to apply Cellzome’s drug discovery and development capabilities and its proprietary Kinobeads™ technology to identify, develop and market novel, kinase-targeted therapeutics to treat inflammatory diseases. GSK has exclusive options to license drug candidates from Cellzome’s kinase programs directed against seven targets.
Cellzome will develop these programs to clinical proof of concept, unless GSK elects to exercise its option earlier, and Cellzome is eligible to receive success-based milestones from GSK as product candidates are advanced. The milestone is the first of such payments under the agreement.
Tim Edwards, CEO of Cellzome, said: “We are making excellent progress on the programs optioned to GSK. The achievement of this first milestone so soon after the start of our collaboration is evidence of this and bears testimony to the power of our Kinobeads™ technology and the quality of our scientists. We look forward to continued success in this alliance.”
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018